European Medicines Agency Recommends Oral GLP-1 for Weight Management and Pancreatic Cancer Treatment

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the authorization of a new once-daily oral GLP-1 medicine for weight management and type 2 diabetes, and Rasonque (Revolution Medicines) for metastatic pancreatic cancer. These recommendations from the October 2026 meeting mark significant steps towards new therapeutic options in the European Union.